Novartis Presentations at the 2023 ASCO Annual Meeting
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Alpelisib (Abstract # 1078)
Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
S. Chia
Alpelisib (Abstract # TPS1117)
EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR–positive, HER2-negative, advanced breast cancer, which progressed on or after aromatase inhibitor treatment in Japan
H. Iwata
Alpelisib (Abstract # e13005)
PI3KCA mutation prevalence and outcome among patients with metastatic breast cancer in Bulgaria treated with first-line endocrine therapy
R. Gencheva
Alpelisib (Abstract # e24199)
Creating patient friendly informed consent form (ICF): Insights from global oncology patient insights panels (GOPIPs)
D. Aubel
Ribociclib (Abstract # 535)
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): a correlation analysis
M. Untch
Ribociclib (Abstract # 542)
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC): a US database analysis
S. Graff
Ribociclib (Abstract # TPS1124)
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer
P. Fasching
Ribociclib (Abstract # TPS1125)
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-Enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study - HARMONIA SOLTI-2101 / AFT-58
T. Pascual
Ribociclib (Abstract # e13050)
Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA
T. Decker
Ribociclib (Abstract # e13054)
Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry
S.W. Lok
Ribociclib (Abstract # e18820)
Adjuvant therapy for HR+/HER2– early-stage breast cancer (EBC): changes in practice patterns among community oncologists in Brazil
A. Goncalves
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Canakinumab (Abstract # e21112)
Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14)
M. Furqan
JDQ443 (Abstract # 9007)
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
P. Cassier
JDQ443 (Abstract # 9117)
Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) in the United States
B. Levy
JDQ443 (Abstract # TPS9144)
KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 versus docetaxel in patients with previously treated, locally advanced or metastatic KRAS G12C-mutated NSCLC
F. Cappuzzo
JDQ443 (Abstract # TPS9158)
A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation
C. Lindsay
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Dabrafenib-Trametinib (Abstract # 9521)
Real-world treatment patterns and clinical outcomes among subgroups of BRAF-positive metastatic melanoma patients treated with dabrafenib + trametinib
Z. Eroglu
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
177Lu-PSMA-617 (Abstract # 5028)
Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: preliminary results
K. Herrmann
177Lu-PSMA-617 (Abstract # 5046)
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study
B. Krause
177Lu-PSMA-617 (Abstract # TPS5116)
PSMAddition: A phase 3 trial to compare treatment with [177Lu]Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer
S. Tagawa
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Myelodysplastic Syndrome & Acute Myeloid Leukemia
Myelodysplastic Syndrome & Acute Myeloid Leukemia
Sabatolimab (Abstract # 7044)
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloidleukemia (AML) in a US RWE database (COTA)
A. Zeidan
Sabatolimab (Abstract # e19077)
Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA)
R. Komrokji
Relapsed Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma
PHE885 (Abstract # 8004)
Updated phase I study results of PHE885, a T-Charge™ manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM)
A. Sperling
Renal Cell Carcinoma
Renal Cell Carcinoma
Pazopanib (Votrient) (Abstract # e16521)
A novel prognostic model for oligometastatic renal cell carcinoma: COMPARZ study post-hoc analysis.
A. Anwaier
Pazopanib (Votrient) (Abstract # e16536)
Long-term liver and renal dysfunction in patients with metastatic renal cell carcinoma treated with TKI monotherapy: COMPARZ study post-hoc analysis.
A. Anwaier
